

REMARKS

Upon entry of the above amendments, claims 8, 10, 16, and 17 are pending. Claims 1 to 7, 9, and 11 to 15 have been cancelled. Applicants have amended the claims to focus on particular embodiments of the invention, to place the claims in form appropriate for U.S. practice, and to reduce the filing fee by, *inter alia*, removing multiple dependencies. Applicants have amended the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper in accordance with U.S. practice.

Accordingly, Applicants believe the present claims are in condition for allowance and such action is requested. If the Examiner has any outstanding issues with regard to the present claims, he is encouraged to telephone the undersigned for expeditious handling.

Respectfully submitted,



Jennifer L. Fox
Attorney for Applicant
Registration No. 52,218

Date: 8 December 05
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-6334
Facsimile: 919-483-7988